41 results
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
26 Sep 23
I.Certification of the Person Responsible for the Half-year Financial Report
3:01pm
34, as adopted by the European Union (EU).
As condensed consolidated financial statements, they do not include all information that would be required
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
24 May 23
Exemption Document Prepared In Connection with the Merger by Absorption of Pherecydes Pharma by Erytech Pharma
8:25am
Union.
Significant changes since the end of the last financial year
Any significant changes having an impact on Erytech’s operations and principal … by the European Union (EU) and audited by the auditors KPMG and RSM; and
The financial statements included in the Annual Financial Report
6-K/A
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
12 Sep 22
I.Certification of the Person Responsible for the Half-year Financial Report
4:33pm
in Ukraine.
In response, the United States, the European Union and certain other countries have imposed significant sanctions and export controls against … States, the European Union and certain other countries could impose further sanctions, trade restrictions, and other retaliatory actions should
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
12 Sep 22
I.Certification of the Person Responsible for the Half-year Financial Report
12:04pm
in Ukraine.
In response, the United States, the European Union and certain other countries have imposed significant sanctions and export controls against … States, the European Union and certain other countries could impose further sanctions, trade restrictions, and other retaliatory actions should
S-8
EX-23.1
PHXM
PHAXIAM Therapeutics S.A.
30 Jun 22
Registration of securities for employees
4:10pm
Paris la Défense Cedex
Capital : 5 497 100 €.
Code APE 6920Z
775 726 417 R.C.S. Nanterre
TVA Union Européenne
FR 77 775 726 417
6-K
EX-99.1
pnmpyz909kk409
28 Apr 22
Asset Purchase Agreement
8:30am
6-K
EX-10.1
ygdvqby5l 1irbgiqv3
16 Dec 21
Erytech Announces Presentation of Results of Expanded Access Program In All at 2021 Ash Annual Meeting and Acceptance of Two Abstracts at Asco Gi
5:23pm
6-K
EX-10.3
w9s29
16 Dec 21
Erytech Announces Presentation of Results of Expanded Access Program In All at 2021 Ash Annual Meeting and Acceptance of Two Abstracts at Asco Gi
5:23pm
424B5
l2ts 3q5zlr0t44fsc
16 Dec 21
Prospectus supplement for primary offering
5:21pm
F-3
EX-23.1
8uquv4rxubny9vq0
21 Sep 21
Shelf registration (foreign)
12:50pm
F-3
qbctj9uwl0iie28d e8v
21 Sep 21
Shelf registration (foreign)
12:50pm
6-K
EX-99.1
uj226u1
20 Sep 21
I.Certification of the Person Responsible for the Half-year Financial Report
1:37pm
S-8
EX-23.1
3bpj16t6g4y70x6ndiu
7 May 21
Registration of securities for employees
4:06pm
424B5
mz7po fbk
5 May 21
Prospectus supplement for primary offering
4:50pm
6-K
EX-10.3
m4sxysobg7 rim
3 May 21
ERYTECH Announces $30.0 Million
5:20pm
6-K
EX-10.1
3oppw cxsm
3 May 21
ERYTECH Announces $30.0 Million
5:20pm
424B5
9tdev
3 May 21
Prospectus supplement for primary offering
5:14pm